Overview
Headquarters
European Union (EU)
Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide. In cancer, personalized medicine uses specific information about a person’s tumor to help diagnose, make a prognosis, plan treatment or to find out how well the treatment is working. Amadix´s personalized medicine strategy aims to provide diagnostic tools that support the physician’s decisions about patient management, in order to give the right treatment to the right patient. As of today, Amadix has a pipeline of innovative and non-invasive tests under development for screening and early diagnostic uses in colon, lung and pancreatic cancer. The company has conducted clinical studies in more than twenty hospitals for different types of cancer. All Amadix products are duly protected by patents worldwide, with patent protection in eleven territories including the US, Europe and Japan. The most advanced product developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients). Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US. https://youtu.be/QxsztlVdlvk Amadix is a biotechnology company focused on the development and commercialization of diagnostic tools for personalized oncology treatment.
